A, ABCD1 allele frequencies. B, ARSA, GALC, and IDUA allele frequencies. For all gene alleles, comparison of each racial population to European non-Finnish population was significant (P < .05).
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Bonkowsky JL, Wilkes J, Bardsley T, Urbik VM, Stoddard G. Association of Diagnosis of Leukodystrophy With Race and Ethnicity Among Pediatric and Adolescent Patients. JAMA Netw Open. 2018;1(7):e185031. doi:10.1001/jamanetworkopen.2018.5031
Are there disparities in leukodystrophy diagnosis in patients of different racial and ethnic backgrounds?
This case-control study of 557 patients with a diagnosis of leukodystrophy found that US patients of racial/ethnic minorities, including those from black, black Hispanic, and white Hispanic backgrounds, were significantly less likely to be diagnosed with a leukodystrophy. Furthermore, leukodystrophy disease–associated gene allele frequencies were the same or higher in populations of Latino or African descent.
Patients of racial/ethnic minorities are being underdiagnosed for leukodystrophies, which can result in a lack of treatment or insufficient treatment.
Inherited leukodystrophies are a group of neurological diseases affecting myelin that cause significant morbidities and death. Timely and correct diagnosis is important for initiating treatment, designing disease screening, and offering care and guidance to patients and families.
To determine whether there are disparities in leukodystrophy diagnosis in different racial backgrounds.
Design, Setting, and Participants
This case-control study involved a retrospective review of patients aged 18 years or younger who were diagnosed with 1 of 4 leukodystrophies (metachromatic leukodystrophy, X-linked adrenoleukodystrophy, Krabbe disease, and Hurler disease) in the US Children’s Hospital Association’s Pediatric Health Information System database from October 1, 2015, through September 30, 2017.
Main Outcomes and Measures
Leukodystrophy diagnosis and racial background of the patients were analyzed. Adjusted prevalence estimates of leukodystrophies were obtained by controlling for sex, insurance type, urban or rural status, 2010 median household income for patient zip code, number of inpatient days, and age at first visit. Pathogenic leukodystrophy gene allele frequencies in different racial backgrounds for ABCD1, ARSA, GALC, and IDUA were determined using the gnomAD database.
Of the 557 patients identified with a leukodystrophy (221 [40%] female; 321 [58%] white non-Hispanic, 54 [10%] black non-Hispanic, and 51 [9%] white Hispanic; median [range] age, 7 [0-18] years), nonwhite race, including black non-Hispanic, black Hispanic, and white Hispanic, was associated with not having a leukodystrophy diagnosis. The adjusted prevalence for a leukodystrophy diagnosis in white non-Hispanic patients was 13.8 (95% CI, 10.6-17.9) per 100 000 patients, compared with 5.8 (95% CI, 3.8-8.9), 2.4 (95% CI, 1.1-5.2), and 7.4 (95% CI, 5.2-10.4) per 100 000 in black non-Hispanic, black Hispanic, and white Hispanic patients, respectively. This reduced rate of diagnosis was out of proportion to the frequency of the different races in the Pediatric Health Information System database. Similar or higher frequencies of missense or loss-of-function alleles were measured in populations of Latino and African descent for the pathogenic leukodystrophy gene alleles. For example, for ABCD1, allele frequencies in those of Latino or African descent were 2.1 × 10−5 and 2.2 × 10−5, as compared with 1.4 × 10−5 for those of European non-Finnish descent.
Conclusions and Relevance
Patients of racial/ethnic minorities, including those from black, black Hispanic, and white Hispanic backgrounds, were significantly less likely to be diagnosed with a leukodystrophy. Leukodystrophy disease–associated allele frequencies were the same or higher in populations of Latino or African descent, arguing against a genetic founder effect being responsible for the lower diagnosis rates. This underdiagnosis has implications for newborn screening programs and treatment access and may reflect a more widespread problem in pediatric neurological and orphan diseases.
Inherited leukodystrophies are a group of diseases affecting myelin that cause significant morbidities and death in 1 of 3 patients by age 8 years.1 Because certain leukodystrophies are clinically distinct, are uniquely diagnosable, and are the subject of extensive outcome and genetic studies, they have the potential to serve as an important proxy for understanding issues related to diagnosis and treatment in pediatric neurological and orphan diseases. Furthermore, children with neurological impairment, including leukodystrophies, account for a large and growing proportion of children’s hospital charges (30%).2
Over the past 2 decades, estimates of the incidence of leukodystrophies have been performed with varying methods at tertiary referral centers and population-based medical centers, as well as using national databases.1,3-12 However, a major limitation is that almost all studies of disease prevalence, outcomes, burden, and treatment have been performed in the United States or Europe, with patients drawn from predominantly Caucasian ancestry.1,3 To our knowledge, the incidence of leukodystrophies in racial/ethnic minority patient populations has not been examined, and it is not known whether diagnosis rates are equivalent in racial/ethnic minority populations, whether mutation rates are similar, and whether disease presentation or response to treatment differ. Because some leukodystrophies are treatable but require timely diagnosis and have therefore been added to newborn screening,13 understanding ethnic and racial differences is critical for effective screening, diagnosis, and treatment. Our objective was to determine whether there are disparities in leukodystrophy diagnosis in different racial backgrounds.
This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort analyses.14 The study, which used deidentified data, was not considered human subjects research and was exempted by the institutional review boards at the University of Utah and Intermountain Healthcare. We conducted a retrospective case-control study on patients aged 18 years or younger admitted to a Pediatric Health Information System (PHIS) hospital with an International Classification of Diseases, Tenth Revision (ICD-10) diagnosis of leukodystrophy (metachromatic leukodystrophy [E75.25], X-linked adrenoleukodystrophy [E71.52x], Krabbe disease [E75.23], or Hurler disease [E76.01]) between October 1, 2015, and September 30, 2017.
The PHIS database has information from more than 50 children’s hospitals in the United States.15 Hospitals are affiliated with the business alliance of Child Health Corporation of America. Each patient has a unique entry, but the data are deidentified. Data collected include patient and visit demographic characteristics such as age, sex, race, insurance type, type of visit, estimated total visit cost, length of stay, ICD coding, and detailed charge information. The hospital visits included primarily inpatient admissions with additional visit types such as emergency department, observation, ambulatory surgery, and clinic visits. Race and ethnicity were collected as patient- or family-reported answers to separate questions at registration: 1 for race and 1 for ethnicity.
Patients with leukodystrophies were identified from any PHIS visit (inpatient, observation, emergency department, ambulatory surgery, clinic visit) as having an ICD-10 code for 1 of the 4 leukodystrophies between October 1, 2015, and September 30, 2017. The control PHIS cohort of patients without leukodystrophy consisted of all other patients identified during the same period with an ICD-10 code for diseases other than leukodystrophy.
We estimated the 2-year point prevalence of composite and individual leukodystrophy diagnoses in racial groups using a generalized linear model with a binomial distribution and logit linkage function. We fit the model with generalized estimating equations to account for correlation between patients within the same hospital. We estimated unadjusted and adjusted point estimates. Adjusted prevalence estimates were obtained by controlling for sex, insurance, urban or rural status, 2010 median household income for patient zip code, number of inpatient days, and age at first PHIS visit. All analyses were 2-sided, and P < .05 was considered statistically significant. Statistical analyses were conducted with SAS statistical software version 9.4 (SAS Institute Inc).
To compare leukodystrophy gene allele frequencies in different racial groups, we calculated missense and loss-of-function frequencies using the gnomAD database16 for ABCD1, ARSA, GALC, and IDUA. We used a Kruskal-Wallis test to determine significance with subsequent χ2 analysis.
We identified 557 patients with leukodystrophies (221 [40%] female; median [range] age, 7 [0-18] years) in the PHIS database over the 2-year period. The most common racial groups represented were white non-Hispanic (321 patients [58%]), black non-Hispanic (54 patients [10%]), and white Hispanic (51 patients [9%]) (Table 1). Patients had metachromatic leukodystrophy (MLD) (ARSA gene; 139 patients [25% of cohort]), X-linked adrenoleukodystrophy (ABCD1; 111 patients [20%]), Krabbe disease (GALC; 56 patients [10%]), or Hurler disease (IDUA; 56 patients [10%]). We chose these 4 ICD-10 leukodystrophy codes because they provided specificity of an individual leukodystrophy genetic diagnosis. In contrast, other leukodystrophies coded using different ICD-10 codes, such as sphingolipidoses, are nonspecific and include a large range of genetically discrete disorders, such as vanishing white matter disease, Canavan disease, and others.
Nonwhite race/ethnicity, including black, black Hispanic, and white Hispanic background, was associated with not having a leukodystrophy diagnosis (Table 2). The adjusted prevalence for a leukodystrophy diagnosis in white non-Hispanic patients was 13.8 (95% CI, 10.6-17.9) per 100 000 patients, compared with 5.8 (95% CI, 3.8-8.9), 2.4 (95% CI, 1.1-5.2), and 7.4 (95% CI, 5.2-10.4) per 100 000 in black non-Hispanic, black Hispanic, and white Hispanic patients, respectively. This reduced rate of diagnosis was out of proportion to the frequency of the different races in PHIS. When each leukodystrophy was singly tested, nonwhite race was also associated with not having a diagnosis (Table 2).
To explore whether lower leukodystrophy gene allele frequencies in nonwhite races might account for lower diagnosis rates, we determined the frequency of missense and loss-of-function alleles in ABCD1, ARSA, GALC, and IDUA (Figure) using the gnomAD database.16 We observed similar or higher frequencies of missense or loss-of-function alleles in populations of Latino and African descent. For ABCD1, allele frequencies in those of Latino or African descent were 2.1 × 10−5 and 2.2 × 10−5, as compared with 1.4 × 10−5 for those of European non-Finnish descent. For ARSA, GALC, and IDUA, allele frequencies in those of Latino or African descent were 2.7 × 10−3 and 3.9 × 10−3 vs 3.1 × 10−3, 4.1 × 10−3 and 5.6 × 10−3 vs 5.0 × 10−3, and 4.8 × 10−3 and 8.0 × 10−3 vs 5.3 × 10−3.
We found that patients of racial/ethnic minorities, including those from black, black Hispanic, and white Hispanic backgrounds, were significantly less likely to be diagnosed with a leukodystrophy. Furthermore, we observed that leukodystrophy disease–associated allele frequencies were the same or higher in populations of Latino or African descent.
There are known examples of genetic founder effects for specific leukodystrophies in some populations. For example, there is a single historical origin of the mutation in ARSA causing MLD in patients of Arabic heritage17 and there is a single origin from the 19th century causing a higher rate of MLD in the western Navajo Nation.18 However, our observation of comparable or higher frequencies of disease gene alleles in different racial backgrounds suggests that a genetic founder effect is unlikely to account for the observed differences in diagnosis.
Strengths of this study are the use of specific ICD-10 codes to track specific leukodystrophy diseases. In the past, tracking outcomes for patients with leukodystrophies has been more difficult because ICD-9 codes have a relatively low specificity to the diagnosis of an inherited leukodystrophy, and relatively complex algorithms had to be used.19 With the use of ICD-10 codes for X-linked adrenoleukodystrophy, MLD, Krabbe disease, and Hurler disease, we were able to track and compare specific leukodystrophies, which would not have been possible using ICD-9 coding or other less specific ICD-10 codes. Finally, the use of the PHIS national database provides a more comprehensive view of trends across the United States for these relatively rare diseases.
Limitations for this study are its use of retrospective data and the limited duration of data collection. The time limitation was necessary because ICD-10 has only been in use for the past 3 years, and ICD-10 code use was necessary to have sufficient specificity in determining diagnoses. We cannot exclude the possibility that the differences observed in diagnosis were related to different rates of hospital admission. For example, perhaps black patients with leukodystrophies were admitted less often to the hospital, or their families did not bring them to the emergency department as often. Another limitation is that PHIS consists primarily of in-hospital data, with less outpatient clinic data, so it is not possible to accurately determine population rates of disease or prevalence. Our analysis of leukodystrophy gene allele frequencies used the data deposited in gnomAD, which may not have the same racial group distributions as PHIS. Further work should be done to better understand the nonwhite distribution of patients with leukodystrophies; because many patients with leukodystrophies report multiple for racial categorization, it is unclear whether this reflects interracial heritage or whether it is due to issues inherent in data collection.
The reason for the disparity in leukodystrophy diagnosis is not clear. Causes could include differences in de novo mutation rates,12 the presence of disease modifier genes, different clinical symptoms in different racial backgrounds, incorrect diagnosis, or lack of access to specialists or to coverage for testing. This underdiagnosis has implications for newborn screening programs and treatment access because false-positive and false-negative rates affect sensitivity and specificity of screening. Furthermore, as our work is, to our knowledge, the first of its kind in pediatric neurological diseases, we are concerned that the findings of underdiagnosis may reflect a more widespread problem in pediatric neurological and orphan diseases.
Accepted for Publication: October 2, 2018.
Published: November 21, 2018. doi:10.1001/jamanetworkopen.2018.5031
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2018 Bonkowsky JL et al. JAMA Network Open.
Corresponding Author: Joshua L. Bonkowsky, MD, PhD, Department of Pediatrics, University of Utah School of Medicine, 295 Chipeta Way, Williams Bldg, Salt Lake City, UT 84108 (firstname.lastname@example.org).
Author Contributions: Dr Bonkowsky had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Bonkowsky, Wilkes, Bardsley.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Bonkowsky, Wilkes.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Wilkes, Bardsley, Urbik, Stoddard.
Administrative, technical, or material support: Bonkowsky, Wilkes.
Conflict of Interest Disclosures: Dr Bonkowsky has served as a consultant to Bluebird Bio, Inc, and has received funding from the European Leukodystrophy Association. No other disclosures were reported.
Funding/Support: Dr Bonkowsky was supported by the National Institutes of Health National Center for Advancing Translational Sciences (grant 3UL1TR002538) and by the University of Utah Bray Chair in Child Neurology Research and Primary Children’s Brain and Spine Center. Messrs Bardsley and Stoddard were supported by the University of Utah Study Design and Biostatistics Center, with funding in part from the National Institutes of Health National Center for Advancing Translational Sciences (grant 8UL1TR000105 [formerly UL1RR025764]). Ms Urbik was supported by the Medical Student Research Program at the University of Utah (National Institutes of Health National Center for Advancing Translational Sciences grant T35HL007744).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Ernest K. Korgenski, MS, Intermountain Healthcare, Salt Lake City, Utah, provided advice on PHIS data. He was not compensated for his contribution.
Create a personal account or sign in to: